Antinuclear antibodies (ANA) in systemic lupus erythematosus (SLE) by immunofluorescence (IFA) and solid phase immunoassay
| Reference | No of SLE patients | IFA (% SLE patients positive) | Solid phase assay (% SLE patients positive) | Solid phase assay method |
|---|---|---|---|---|
| 9 | 55 | 91% (1:80)* | 87% 89% | Radim SpA EIA Zeus |
| 78% | EIA VarElisa ReCombi | |||
| (Pharmacia) | ||||
| 11 | 53 | 91% (>1:50) | 49% | Athena Multilyte |
| 16 | 71 (including SLE, DLE, drug-induced) | 98% (1:40) | 91% | RADIAS (Bio-Rad) |
| 17 | 34 | 76% (>1:160) | 62% | ELIA Pharmacia |
| 19 | 202 | 87% | 75% | VarElisa ELISA |
| 30 | 50 | 84% at 1:50 | 40% | AntiNucleosomes GmbH |
| 80% at 1:100 76% at 1:200 | 56% | QUANTA Lite (INOVA) | ||
| 28 | 38 | 92% | 79% | QUANTA Lite (INOVA) |
| 32 | 192 | 99% (81%)† | 75.50% | Bioplex |
| 33 | 35 | 97% (>1:160) | 100% 94% | Quanta Life Bio-Rad |
| 100% | Relisa | |||
| 60% | VarElisa | |||
| 62% | UniCap |
↵* Indicates the dilution used if reported in the paper.
† Two different percentages are reported in the paper.